Bapi Pahar

Nov 16, 2024 | nature.com | Brian Carey |Chengjin Ye |Monika Mehta |Bapi Pahar |Scott Anthony |Anthony Marketon | +2 more

AbstractLassa virus (LASV) is a rodent-borne mammarenavirus that causes tens to hundreds of thousands of human infections annually in Western Africa. Approximately 20% of these infections progress to Lassa fever (LF), an acute disease with case–fatality rates from ≈20–70%. Currently, there are no approved vaccines or specific therapeutics to prevent or treat LF. The LASV genome consists of a small (S) segment that has two genes, GP and NP, and a large (L) segment that has two genes, L and Z.

Nov 4, 2023 | nature.com | Ivy Phung |Kristen A. Rodrigues |Ester Marina-Zárate |Bapi Pahar |Wen-Hsin Lee |Pyone P. Aye | +13 more

AbstractAdjuvants and antigen delivery kinetics can profoundly influence B cell responses and should be critically considered in rational vaccine design, particularly for difficult neutralizing antibody targets such as human immunodeficiency virus (HIV). Antigen kinetics can change depending on the delivery method.